Literature DB >> 12151841

Neuropsychiatric symptoms in the dementias.

Frédéric Assal1, Jeffrey L Cummings.   

Abstract

PURPOSE OF REVIEW: Neuropsychiatric, or non-cognitive symptoms are increasingly recognized as manifestations of dementias. RECENT
FINDINGS: In Alzheimer's disease, recent advances have included the identification of behavioral profiles, differentiation of apathy and depression, characterization of risk factors for psychosis and its links to agitation and aggression, and an analysis of depressive symptoms in the absence of major depression. Functional neuroimaging data mainly supported the role of the anterior cingulate in apathy. The orbitofrontal and anterior cingulate tangle burden were associated with agitation, and increased orbitofrontal and mid-temporal muscarinic M2 receptors with psychosis and hallucinations. Selected genetic polymorphisms of dopamine and serotonin receptors or transporters were linked with aggression, hallucinations or psychosis. When compared with other dementias, individuals with frontotemporal dementia disclosed, as expected, different behaviors and particularly aberrant social behavior. The frequency of delusions and visual hallucinations was increased in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies, suggesting common mechanisms such as Lewy body pathology and cholinergic deficiency. The latter was supported by an improvement of these symptoms by cholinesterase inhibitors.
SUMMARY: Future research directions include both clinical and basic neuroscience investigations. The detection of early neuropsychiatric symptoms might be a marker for dementia, and the possible existence of a mild neuropsychiatric impairment syndrome should be explored. More longitudinal studies with pathological confirmation will facilitate correlations with neuropsychiatric symptoms. Functional neuroimaging and behavioral neurogenetics will permit in-vivo correlations and consequently help patient management and care.

Entities:  

Mesh:

Year:  2002        PMID: 12151841     DOI: 10.1097/00019052-200208000-00007

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  44 in total

1.  Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.

Authors:  Florian G Metzger; Ann-Christine Ehlis; Florian B Haeussinger; Andreas J Fallgatter; Katja Hagen
Journal:  Psychopharmacology (Berl)       Date:  2015-09-11       Impact factor: 4.530

2.  BACE1 and presenilin/γ-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels.

Authors:  Carolyn C Sachse; Young Hye Kim; Marianne Agsten; Tobias Huth; Christian Alzheimer; Dora M Kovacs; Doo Yeon Kim
Journal:  FASEB J       Date:  2013-03-15       Impact factor: 5.191

3.  The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults.

Authors:  Lauren A Rog; Lovingly Quitania Park; Danielle J Harvey; Chun-Jung Huang; Scott Mackin; Sarah Tomaszewski Farias
Journal:  Clin Neuropsychol       Date:  2014-02-06       Impact factor: 3.535

Review 4.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

5.  Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?

Authors:  M Colaianna; P Tucci; M Zotti; M G Morgese; S Schiavone; S Govoni; V Cuomo; L Trabace
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

6.  BACE1 regulates voltage-gated sodium channels and neuronal activity.

Authors:  Doo Yeon Kim; Bryce W Carey; Haibin Wang; Laura A M Ingano; Alexander M Binshtok; Mary H Wertz; Warren H Pettingell; Ping He; Virginia M-Y Lee; Clifford J Woolf; Dora M Kovacs
Journal:  Nat Cell Biol       Date:  2007-06-18       Impact factor: 28.824

7.  Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia.

Authors:  Emily R Edwards; Adam P Spira; Deborah E Barnes; Kristine Yaffe
Journal:  Int J Geriatr Psychiatry       Date:  2009-07       Impact factor: 3.485

8.  Visual Hallucinations.

Authors:  Victoria S. Pelak; Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

9.  Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease.

Authors:  Yosef A Berlow; William M Wells; James M Ellison; Young Hoon Sung; Perry F Renshaw; David G Harper
Journal:  Int J Geriatr Psychiatry       Date:  2010-08       Impact factor: 3.485

10.  Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.

Authors:  Josef Marksteiner; Reinhold Schmidt
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.